We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+9.35%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$6.46B
AUM Growth
-$2.68M
Cap. Flow
-$106M
Cap. Flow %
-1.64%
Top 10 Hldgs %
39.36%
Holding
145
New
22
Increased
28
Reduced
21
Closed
17

Top Buys

Rank Stock Value
1
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
+$201M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$91.6M
3
QURE icon
uniQure
QURE
+$57.2M
4
NTRA icon
Natera
NTRA
+$47.4M
5
ATNX
Athenex, Inc. Common Stock
ATNX
+$47.3M

Top Sells

Rank Stock Value
1
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$272M
2
GH icon
Guardant Health
GH
+$118M
3
VTRS icon
Viatris
VTRS
+$77.1M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$64M
5
HUM icon
Humana
HUM
+$55.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.58%
2 Financials 1.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRCA icon
76
Verrica Pharmaceuticals
VRCA
$92.8M
$17.2M 0.27%
147,973
– –
NVO
77
Novo Nordisk
NVO
$225B
$16.8M 0.26%
660,000
– –
SVA
78
DELISTED
Sinovac Biotech, Ltd
SVA
$16.6M 0.26%
2,839,500
– –
ALPN
79
DELISTED
Alpine Immune Sciences Inc
ALPN
$15.5M 0.24%
3,670,955
– –
SYRE icon
80
Spyre Therapeutics
SYRE
$8.68B
$14.8M 0.23%
86,621
– –
ABBV icon
81
CALL
AbbVie
ABBV
$465B
$14.5M 0.23%
+200,000
New +$15.7M
XFOR icon
82
X4 Pharmaceuticals
XFOR
$371M
$14M 0.22%
31,216
+20,833
+201% +$10.6M
AMRN
83
Amarin Corp
AMRN
$293M
$13.9M 0.22%
35,880
+12,500
+53% +$4.58M
TAK icon
84
Takeda Pharmaceutical
TAK
$56B
$13.3M 0.21%
750,000
– –
PRQR icon
85
ProQR Therapeutics
PRQR
$248M
$12.6M 0.19%
1,382,502
-599,529
-30% -$7.07M
FOMX
86
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$12.4M 0.19%
5,195,330
– –
IMMU
87
DELISTED
Immunomedics Inc
IMMU
$11.3M 0.18%
818,200
-3,452,203
-81% -$51.9M
NBRV
88
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$11.3M 0.17%
18,578
– –
SYK icon
89
Stryker
SYK
$133B
$11.1M 0.17%
54,000
– –
ARQL
90
DELISTED
Arqule Inc
ARQL
$11M 0.17%
+1,000,000
New +$6.96M
SCPH
91
DELISTED
scPharmaceuticals
SCPH
$10.9M 0.17%
3,409,865
– –
PFE icon
92
PUT
Pfizer
PFE
$144B
$10.8M 0.17%
+263,500
New +$10.5M
CNST
93
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$10.3M 0.16%
835,842
– –
RETA
94
PUT
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$9.44M 0.15%
+100,000
New +$8.63M
PSNL icon
95
Personalis
PSNL
$1.27B
$8.14M 0.13%
+300,000
New +$8.48M
PBYI icon
96
Puma Biotechnology
PBYI
$406M
$7.93M 0.12%
624,249
-1,255,751
-67% -$28.9M
MRSN
97
DELISTED
Mersana Therapeutics
MRSN
$7.66M 0.12%
75,645
– –
ASMB icon
98
Assembly Biosciences
ASMB
$507M
$7.06M 0.11%
43,633
-39,377
-47% -$7.48M
GILD icon
99
CALL
Gilead Sciences
GILD
$167B
$6.76M 0.1%
+100,000
New +$6.58M
FOLD
100
DELISTED
Amicus Therapeutics
FOLD
$6.47M 0.1%
518,309
– –
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q2 2019 Portfolio in Review

As of Q2 2019, OrbiMed held 145 positions worth $6.46B, down 0.04% from $6.46B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

OrbiMed's Q2 2019 filing shows 22 new, 28 increased, 21 reduced and 17 closed positions. Its largest new stake was Prevail Therapeutics Inc. Common Stock: 13,822,463 shares worth $182M. The largest sale was Clementia Pharmaceuticals Inc., an estimated $272M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q2 2019 buy was Prevail Therapeutics Inc. Common Stock: 13,822,463 shares worth $182M.
  • OrbiMed added most to Natera in Q2 2019, an estimated $47.4M increase.
  • OrbiMed's biggest Q2 2019 reduction was Viatris, cutting an estimated $77.1M.
  • OrbiMed fully exited Clementia Pharmaceuticals Inc. in Q2 2019, selling an estimated $272M.
  • OrbiMed's ten largest holdings make up 39% of its $6.46B portfolio in Q2 2019.
  • OrbiMed opened 22 new positions and closed 17 in Q2 2019.
  • OrbiMed's portfolio value fell 0.04% quarter-over-quarter to $6.46B.

Based on OrbiMed's 13F filing for Q2 2019, filed 14 Aug 2019.